Abstract: microRNAs and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone-associated medical conditions are provided.
Abstract: The present invention provides double-stranded RNA molecules that mediate RNA interference in target cells, preferably hepatic cells. The invention also provides double-stranded RNA molecules that are modified to be resistant to nuclease degradation, which inactivates a virus, and more specifically, hepatitis C virus (HCV). The invention also provides a method of using these modified RNA molecules to inactivate virus in mammalian cells and a method of making modified small interfering RNAs (siRNAs) using human Dicer.
Type:
Grant
Filed:
March 12, 2013
Date of Patent:
September 22, 2015
Assignee:
Arrowhead Research Corporation
Inventors:
Jang Han, Mi-Young Seo, Michael Houghton
Abstract: The invention provides methods for determining whether a subject is suffering from a rheumatoid arthritis associated with the BRAF oncogene comprising contacting isolated fibroblasts from the subject with a molecule or pool of molecules directed to the BRAF oncogene; and culturing the sample in the presence of the agent and determining whether BRAF oncogene expression by the cell is decreased and/or whether cells in the sample return to a less transformed phenotype, exhibit decreased cell proliferation and/or exhibit increased contact inhibition, any of which is indicative that the subject is suffering from a rheumatoid arthritis associated with the BRAF oncogene.
Type:
Grant
Filed:
March 18, 2014
Date of Patent:
September 15, 2015
Assignee:
The United States of America as represented by the Department of Veterans Affairs
Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the KLF1 gene and the BCL11A gene, and methods of using such dsRNA compositions to inhibit expression of KLF1 and BCL11 A, respectively.
Type:
Grant
Filed:
December 9, 2011
Date of Patent:
September 8, 2015
Assignee:
Alnylam Pharmaceuticals, Inc.
Inventors:
Tatiana Novobrantseva, Brian Bettencourt, Stuart Milstein, Anna Borodovsky
Abstract: The present invention relates to evaluating the prognosis of patients with estrogen receptor-positive breast cancer on the basis of Rab27B expression. The invention further relates to a kit comprising an assay for measuring Rab27B levels in said patients and to the usage of Rab27B as a target to screen for drugs capable of inhibiting or diminishing metastasis of said cancer. Furthermore, the invention discloses compounds which can be used to treat estrogen receptor-positive breast cancer.
Type:
Grant
Filed:
May 12, 2010
Date of Patent:
August 11, 2015
Assignee:
Universiteit Gent
Inventors:
Olivier De Wever, An Hendrix, Wendy Westbroek
Abstract: This document relates to methods and materials for determining whether or not a horse contains a Grey allele. For example, diagnostic methods such as nucleic acid-based detection methods and materials such as nucleic acid probes and primer pairs that can be used to determine whether or not a horse contains a duplication in intron 6 of STX17 nucleic acid are provided. This document also relates to methods and materials for treating a mammal having or being likely to develop cancer (e.g., benign, malignant, or metastatic cancer). For example, methods and materials for treating cancer in a mammal by administering an agent having the ability to reduce expression of an STX17 polypeptide and/or an NR4A polypeptide (e.g., an NR4A1, NR4A2, or NR4A3 polypeptide) in the mammal are provided.
Type:
Grant
Filed:
September 4, 2012
Date of Patent:
August 4, 2015
Assignee:
Biocistronix AB
Inventors:
Leif Andersson, Gerli Rosengren Pielberg, Anna Olegovna Golovko, Kjell Robert Johan Lennartsson, Carl-Henrik Heldin
Abstract: This invention relates generally to segmented oligonucleotides capable of modulating gene expression. Specifically, the instant invention relates to segmented microRNA (miRNA) oligonucleotides, including segmented miRNA precursors and segmented pre-microRNAs. The invention also relates to compositions comprising such segmented oligonucleotides, as well as to methods of making and using such oligonucleotides for diagnosis and treatment of diseases associated or causally linked to aberrant levels or activities of gene expression, including aberrant levels of coding and/or non-coding RNA.
Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Sirtuin (SIRT), in particular, by targeting natural antisense polynucleotides of a Sirtuin (SIRT). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Sirtuins (SIRT)s.
Type:
Grant
Filed:
January 13, 2011
Date of Patent:
July 28, 2015
Assignee:
CuRNA, Inc.
Inventors:
Joseph Collard, Olga Khorkova Sherman, Carlos Coito, Belinda De Leon
Abstract: The present invention relates to a kit for the diagnosis or screening of asthma comprising neuropilin (NRP) gene, and to a method for screening a therapeutic agent for asthma using the same. More precisely, the present invention confirmed that NRP1 expression was increased in asthma patients and by D. pteronissinus extract. Based on the confirmation, the inventors confirmed that NRP1 could be effectively used as a target for the development of a therapeutic agent for asthma since the suppression of NRP1 expression resulted in the decrease of mRNA, protein, enzyme activity, and promoter activity of MMP-9 in relation to asthma.
Type:
Grant
Filed:
July 1, 2011
Date of Patent:
July 14, 2015
Assignee:
Korea Research Institute of Bioscience and Biotechnology
Inventors:
Hyeong Kyu Lee, Kyung Seop Ahn, Yoosik Yoon, Byoung Whui Choi, Ok-Kyoung Kwon, Semi Kim, Hui Seong Kim, Sei Ryang Oh, Ji Eun Yuk, Ha Young Jang
Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Brain derived neurotrophic factor (BDNF), in particular, by targeting natural antisense polynucleotides of Brain derived neurotrophic factor (BDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of BDNF.
Type:
Grant
Filed:
February 12, 2010
Date of Patent:
July 7, 2015
Assignee:
CuRNA, Inc.
Inventors:
Joseph Collard, Olga Khorkova Sherman, Carlos Coito
Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Uncoupling Protein 2 (UCP2), in particular, by targeting natural antisense polynucleotides of Uncoupling Protein 2 (UCP2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of UCP2.
Abstract: The present invention relates to antagonists of the expression and/or the function of the micro RNA miRNA-29 for use in the prevention and/or treatment of aortic aneurysms. Further disclosed is a method for the identification of miRNA-29 antagonists, a pharmaceutical composition comprising said miRNA-29 antagonists and a method for preventing and treating age-related aortic aneurysm formation in a subject in need of such a treatment.
Type:
Grant
Filed:
April 1, 2011
Date of Patent:
June 23, 2015
Assignee:
Johann Wolfgang Goethe-Universität Frankfurt am Main
Inventors:
Andreas Zeiher, Stefanie Dimmeler, Reinier Boon
Abstract: Long non-coding RNAs (lncRNAs) and methods of using them diagnostically and therapeutically for treatment of cancer, stem cell therapy, or regenerative medicine are disclosed. In particular, the invention relates to lncRNAs that that play roles in regulation of genes involved in cell proliferation, differentiation, and apoptosis. Such lncRNAs can be used as biomarkers to monitor cell proliferation and differentiation during cancer progression or tissue regeneration. One of the identified lncRNAs, referred to as PANDA (a P21-Associated NcRNA, DNA damage Activated), inhibits the expression of apoptotic genes normally activated by the transcription factor NF-YA. Inhibitors of PANDA sensitize cancerous cells to chemotherapy and can be used in combination with chemotherapeutic agents for treatment of cancer.
Type:
Grant
Filed:
September 7, 2013
Date of Patent:
June 23, 2015
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Howard Y. Chang, David J. Wong, Tiffany Hung
Abstract: Compositions comprising therapeutic oligonucleotide compounds that target the expression of genes associated with tumorigenesis or cell transformation are provided. Methods are described to manipulate and treat the oncogenic deregulation of the TP53-associated apoptosis pathway. Markers for acute myeloid leukemia (AML) and uses thereof are described.
Type:
Grant
Filed:
April 1, 2013
Date of Patent:
June 16, 2015
Assignee:
The Ohio State University
Inventors:
Albert de la Chapelle, Ann-Kathrin Eisfeld
Abstract: The present invention relates to a method for sensitizing a disease cell expressing the epidermal growth factor receptor (EGFR) to a tyrosine kinase inhibitor selective or specific for EGFR and/or its signalling pathway, the method comprising contacting the cell with a miR-7 miRNA, a precursor or variant thereof, or a miRNA comprising a seed region comprising the sequence GGAAGA.
Type:
Grant
Filed:
November 24, 2010
Date of Patent:
June 9, 2015
Assignee:
The University of Western Australia
Inventors:
Peter Jeffery Leedman, Keith Michael Giles, Felicity Caris Kalinowski
Abstract: A method of (a) treating a lymphoproliferative disease in a subject in need thereof; (b) slowing the progression of lymphoproliferative disease in a subject who has been diagnosed with a lymphoproliferative disease; or (c) preventing or delaying development of a lymphoproliferative disease in a subject who is at risk of developing a lymphoproliferative disease. The method generally comprises administering to the individual an effective amount of a combination therapy comprising: i) at least one autophagy modulating agent, or a derivative, pharmaceutically acceptable salt thereof, or prodrug thereof; and ii) at least one CDK inhibitor agent, or a derivative, pharmaceutically acceptable salt thereof, or prodrug thereof, wherein the i) agent and the ii) agents are administered in amounts sufficient to enhance the cytotoxicity of the combination relative to the CDK inhibitor agent treatment alone.
Type:
Grant
Filed:
November 7, 2011
Date of Patent:
June 2, 2015
Assignee:
The Ohio State University
Inventors:
John C. Byrd, Amy J. Johnson, Emilia Mahoney, David M. Lucas, Michael R. Grever
Abstract: A method of treating autoimmune and inflammatory diseases or conditions in a mammal, such as a human, which comprises the administration of a inhibitor of bromodomain-containing protein: SP140.
Abstract: The present invention provides a prophylactic or therapeutic drug for diabetes, which contains a polynucleotide such as miR-199b* and the like. Moreover, the present invention provides a method for screening for a prophylactic or therapeutic drug for diabetes, which includes measuring an expression level of a polynucleotide such as miR-199b* and the like. Furthermore, the present invention provides a method for determining the susceptibility to a prophylactic or therapeutic drug for diabetes, which includes measuring an expression level of a polynucleotide such as miR-199b* and the like.
Abstract: Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a huntingtin gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate Huntington's Disease (HD).
Type:
Grant
Filed:
February 8, 2011
Date of Patent:
April 14, 2015
Assignees:
Isis Pharmaceuticals, Inc., The University of British Columbia
Inventors:
C. Frank Bennett, Michael Hayden, Susan M. Freier, Sarah Greenlee, Jeffrey Carroll, Simon Warby, Eric E. Swayze
Abstract: Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR-21 activity. The compositions may be used to inhibit miR-21, and also to treat diseases associated with abnormal expression of miR-21, such as fibrosis and cancer.